These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 20346012

  • 1. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
    Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P.
    Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
    [Abstract] [Full Text] [Related]

  • 2. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME, Black KL, Bauman ML, Belletrutti M, Bajzar L, Massicotte MP.
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [Abstract] [Full Text] [Related]

  • 3. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA, Gurian M, Hegyi T, Drachtman RA.
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [Abstract] [Full Text] [Related]

  • 4. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C, Omran H, Tripp C, Poetzsch B.
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [Abstract] [Full Text] [Related]

  • 5. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
    Sanchez de Toledo J, Gunawardena S, Munoz R, Orr R, Berry D, Sonderman S, Krallman S, Shiderly D, Wang L, Wearden P, Morell VO, Chrysostomou C.
    Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK, Shelton CM, Sahni JK, Christensen ML.
    Ann Pharmacother; 2012 Apr; 46(7-8):943-51. PubMed ID: 22828970
    [Abstract] [Full Text] [Related]

  • 9. Variability of plasma anti-Xa activities with different lots of enoxaparin.
    Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT.
    Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
    [Abstract] [Full Text] [Related]

  • 10. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D.
    Circulation; 2004 Jul 27; 110(4):392-8. PubMed ID: 15249498
    [Abstract] [Full Text] [Related]

  • 11. Increased enoxaparin dosing is required for obese children.
    Lewis TV, Johnson PN, Nebbia AM, Dunlap M.
    Pediatrics; 2011 Mar 27; 127(3):e787-90. PubMed ID: 21321026
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS.
    Pharmacotherapy; 2007 Sep 27; 27(9):1263-71. PubMed ID: 17723080
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G.
    Crit Care Med; 2003 May 27; 31(5):1405-9. PubMed ID: 12771610
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
    Tetri S, Hakala J, Juvela S, Saloheimo P, Pyhtinen J, Rusanen H, Savolainen ER, Hillbom M.
    Thromb Res; 2008 May 27; 123(2):206-12. PubMed ID: 18420258
    [Abstract] [Full Text] [Related]

  • 18. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels.
    Gyamfi C, Cohen R, Desancho MT, Gaddipati S.
    J Matern Fetal Neonatal Med; 2005 Nov 27; 18(5):329-31. PubMed ID: 16390793
    [Abstract] [Full Text] [Related]

  • 19. Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring.
    Rojnuckarin P, Akkawat B, Juntiang J.
    Clin Appl Thromb Hemost; 2010 Jun 27; 16(3):313-7. PubMed ID: 19520682
    [Abstract] [Full Text] [Related]

  • 20. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA, Kim S, Moffett BS, Bomgaars L, Mahoney D, Yee DL.
    J Pediatr; 2013 Feb 27; 162(2):293-6. PubMed ID: 22959138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.